These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
684 related articles for article (PubMed ID: 32072746)
1. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status. Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746 [TBL] [Abstract][Full Text] [Related]
2. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Mak KS; Gainor JF; Niemierko A; Oh KS; Willers H; Choi NC; Loeffler JS; Sequist LV; Shaw AT; Shih HA Neuro Oncol; 2015 Feb; 17(2):296-302. PubMed ID: 25053852 [TBL] [Abstract][Full Text] [Related]
3. Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy. Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS; Patel PR; Curran WJ; Shu HG; Sica GL; Higgins KA Cancer; 2018 Sep; 124(17):3586-3595. PubMed ID: 30120912 [TBL] [Abstract][Full Text] [Related]
4. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis. Balasubramanian SK; Sharma M; Venur VA; Schmitt P; Kotecha R; Chao ST; Suh JH; Angelov L; Mohammadi AM; Vogelbaum MA; Barnett GH; Jia X; Pennell NA; Ahluwalia MS Neuro Oncol; 2020 Feb; 22(2):267-277. PubMed ID: 31648302 [TBL] [Abstract][Full Text] [Related]
5. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status. Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827 [TBL] [Abstract][Full Text] [Related]
6. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Lee HL; Chung TS; Ting LL; Tsai JT; Chen SW; Chiou JF; Leung HW; Liu HE Radiat Oncol; 2012 Oct; 7():181. PubMed ID: 23110940 [TBL] [Abstract][Full Text] [Related]
7. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650 [TBL] [Abstract][Full Text] [Related]
8. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627 [TBL] [Abstract][Full Text] [Related]
9. Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation? Wang TJ; Saad S; Qureshi YH; Jani A; Nanda T; Yaeh AM; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Lesser J; Halmos B; Stoopler MB; Lassman AB; Cheng SK; Isaacson SR Neuro Oncol; 2015 Jul; 17(7):1022-8. PubMed ID: 25910841 [TBL] [Abstract][Full Text] [Related]
10. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib. Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598 [TBL] [Abstract][Full Text] [Related]
11. Adverse Events of Concurrent Radiotherapy and ALK Inhibitors for Brain Metastases of ALK-Rearranged Lung Adenocarcinoma. Nakashima T; Nonoshita T; Hirata H; Inoue K; Nagashima A; Yoshitake T; Asai K; Shioyama Y In Vivo; 2020; 34(1):247-253. PubMed ID: 31882485 [TBL] [Abstract][Full Text] [Related]
12. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879 [TBL] [Abstract][Full Text] [Related]
13. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases. Yu X; Sheng J; Pan G; Fan Y Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485 [TBL] [Abstract][Full Text] [Related]
14. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532 [TBL] [Abstract][Full Text] [Related]
15. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997 [TBL] [Abstract][Full Text] [Related]
16. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations. Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228 [TBL] [Abstract][Full Text] [Related]
17. Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery. Shin SM; Cooper BT; Chachoua A; Butler J; Donahue B; Silverman JS; Kondziolka D J Neurooncol; 2016 Feb; 126(3):483-91. PubMed ID: 26520640 [TBL] [Abstract][Full Text] [Related]
18. Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies. Bauml J; Mick R; Zhang Y; Watt CD; Vachani A; Aggarwal C; Evans T; Langer C Clin Lung Cancer; 2013 Sep; 14(5):581-91. PubMed ID: 23827517 [TBL] [Abstract][Full Text] [Related]
19. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India. Patel A; Batra U; Prasad KT; Dabkara D; Ghosh J; Sharma M; Singh N; Suresh P; Jain P; Malik PS; Choudhary P; Ganguly S; Khurana S; Ms S; Bothra S; Muthu V; Biswas B Curr Probl Cancer; 2020 Jun; 44(3):100571. PubMed ID: 32234264 [TBL] [Abstract][Full Text] [Related]
20. Intracranial disease control for EGFR-mutant and ALK-rearranged lung cancer with large volume or symptomatic brain metastases. Dutta SW; Mack ML; Aliotta E; Ward KA; Muller DA; Larner JM; Fadul CE; Hall RD; Gentzler RD; Sheehan JP J Neurooncol; 2020 Sep; 149(2):357-366. PubMed ID: 32902767 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]